Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acomplia Launch Could Come This Year, Sanofi-Aventis Says

Executive Summary

Sanofi-Aventis' weight loss/smoking cessation agent Acomplia (rimonabant) could be launched as early as the end of the year, Exec VP-Pharmaceutical Operations Hanspeter Spek said

You may also be interested in...



Drug Approvals Will Be Down “Significantly” In ’05, FDA’s Gottlieb Predicts

The number of new molecular entities approved by FDA in 2005 will be significantly fewer than in recent years, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb predicted

Drug Approvals Will Be Down “Significantly” In ’05, FDA’s Gottlieb Predicts

The number of new molecular entities approved by FDA in 2005 will be significantly fewer than in recent years, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb predicted

Takeda To Highlight Rozerem Melatonin Receptor Mechanism Of Action

Takeda's Rozerem promotions will highlight ramelteon's melatonin receptor activity and lack of abuse potential following FDA approval of the insomnia therapy

Related Content

Topics

UsernamePublicRestriction

Register

PS045832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel